OR4X1 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Adenosine receptor antagonist that blocks the neuromodulatory effects of adenosine. By inhibiting adenosine's action, caffeine can lead to a decrease in cyclic AMP (cAMP) levels, which are known to regulate OR4X1 function by modulating the signaling cascade that activates the receptor. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
As an inhibitor of voltage-gated potassium channels, quinine can alter the membrane potential and thus influence the signaling pathways that lead to the activation of OR4X1. Changes in ion flow can indirectly inhibit the activity of OR4X1 by disrupting the normal polarization states required for receptor activation. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Sodium channel blocker that can inhibit action potentials in neurons. By reducing neuronal excitability, lidocaine can decrease the likelihood of OR4X1 activation as action potentials are necessary for the initiation of signaling cascades leading to OR4X1 activation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Sirtuin activator that can modulate the cellular environment, leading to alterations in G-protein-coupled receptor (GPCR) activity, including OR4X1. Its modulation of sirtuins can indirectly lead to the inhibition of OR4X1 by altering the intracellular processes that support receptor function. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Diuretic that blocks epithelial sodium channels. By affecting sodium homeostasis, amiloride can influence the electrochemical gradient essential for OR4X1 signaling, indirectly leading to the receptor's inhibition. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Known for altering endosomal and lysosomal pH, chloroquine can interfere with the trafficking of GPCRs to the membrane, potentially reducing OR4X1's presence on the cell surface and its ability to respond to ligands. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker that can reduce calcium influx, an essential part of the signaling cascade that activates OR4X1. By inhibiting this pathway, verapamil can indirectly decrease OR4X1 activity. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Similar to verapamil, diltiazem is also a calcium channel blocker that can impede signaling pathways vital for OR4X1 activation by limiting calcium's intracellular roles. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Another calcium channel blocker that can hinder calcium-dependent processes, including those that regulate the function and activation of OR4X1. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $53.00 $88.00 | 6 | |
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis. Prostaglandins can modulate GPCR signaling, hence ibuprofen may indirectly inhibit OR4X1 by altering prostaglandin levels. | ||||||